Psychedelics: A Working Draft

Working Draft v0.1

SHA-256: ba8ff81d524c23c4651fe153a0e2d09d916b90b20164f7d344ec9503db37ce38

Summary

Objective

This paper asks a narrower and more disciplined question than "are psychedelics permissible in Islam" — it asks whether classical psychedelics (mainly psilocybin and 5-MeO-DMT) actually meet the classical juristic criteria for muskir, the ḥadd-bearing category that governs khamr, and works through that classification question using the tradition's own tools rather than assuming an answer.

Key Arguments

  • Classical psychedelics don't meet the criteria for muskir — a finding reached five separate, independent ways, holding even at the highest doses where earlier drafts of this paper conceded the classification failed
  • The classical taxonomy distinguishes muskir (intoxication with nashwa — elation, boldness) from mukhaddir and muraqqad (clouding or sensory shutdown without it), and psilocybin's evidenced profile tracks the latter, not the former
  • Medical use stands on double-grounded footing: the classification finding above, plus independent support from darūra/ḥāja (necessity and need), on the same precedent as surgical anaesthesia
  • Spiritual use is also supported, but on narrower, single-stranded ground — via the samā' precedent and the Prophet's own i'tikāf and retreat at Ḥirā' — and the paper says plainly where this application is weaker than the medical one

Theological Context

The argument sits inside established methodology rather than outside it — taḥqīq al-manāt, the process of testing whether a new case actually falls under an existing ruling's cause ('illa). It engages the khamr prohibition directly (conceding the drop-rule and ḥadd-attaches-to-the-act principle in full), works through al-Qarāfī's four-part taxonomy of intoxicating substances, and tests Ibn Taymiyya's own criteria — including his banj ruling — on their own terms rather than around them.

Conclusions

Medical use of classical psychedelics is defensible on established Islamic legal principle for conditions like treatment-resistant depression and PTSD, under supervised, purpose-limited, clinically-administered conditions.

Spiritual use is also supported, though on thinner ground. Neither is unrestricted — both stay bounded by supervision and defined purpose, with recreational or unsupervised use excluded throughout.

The paper treats this as a working draft: nine objections are answered directly, several honestly left unresolved rather than papered over, and the whole argument is offered for scrutiny rather than presented as settled.

View Original Paper

1 / 0 100%